I-BET-762: Selective BET Bromodomain Inhibitor for Inflammation and Cancer Research

Executive Summary: I-BET-762 is a highly selective, nanomolar-potency inhibitor of the bromodomain and extra-terminal (BET) family, with IC₅₀ values between 32.5 and 42.5 nM and high binding affinity (K_d 50.5–61.3 nM) for BET acetyl-lysine pockets (APExBIO). It competitively displaces acetyl-lysine residues, downregulating LPS-inducible cytokine gene expression and exhibiting anti-inflammatory effects in mouse models (Fan et al. 2024). I-BET-762 potentiates ferroptosis in various cancer cell lines by promoting ROS accumulation and FSP1 downregulation. Its high selectivity ensures minimal off-target bromodomain inhibition, and it is widely used in epigenetic, inflammation, and cancer biology research (Related review).

Biological Rationale

Bromodomain and extra-terminal (BET) proteins, such as BRD4, are epigenetic readers that bind acetylated lysine residues on histones. This interaction facilitates transcriptional activation of inflammatory and oncogenic genes. BET-mediated transcription is crucial for LPS-induced cytokine and chemokine expression, driving inflammation and tumor progression (Fan et al. 2024). Inhibition of BET proteins disrupts these pathways, offering a precise strategy for modulating transcriptional regulation in inflammatory and neoplastic diseases. I-BET-762 targets BET proteins with nanomolar potency and high selectivity, enabling robust modulation of gene expression without significant interaction with non-BET bromodomains (APExBIO).

Mechanism of Action of I-BET-762

I-BET-762 binds competitively to the acetyl-lysine (AcK) binding pocket of BET proteins. The binding affinity (K_d 50.5–61.3 nM) and IC₅₀ values (32.5–42.5 nM) reflect its strong, selective inhibition (APExBIO). Structural studies show a 2:1 binding ratio, enhancing selectivity and efficacy. Upon binding, I-BET-762 displaces endogenous acetyl-lysine residues, preventing BET proteins from recruiting transcriptional machinery to target gene promoters. This leads to downregulation of LPS-inducible cytokines and chemokines, such as TNF-α and IL-6 (Fan et al. 2024).

In cancer cells, I-BET-762-induced BRD4 inhibition enhances erastin-induced ferroptosis, an iron-dependent form of cell death. This effect is mediated by increased reactive oxygen species (ROS) and reduced expression of ferroptosis suppressor protein 1 (FSP1), a key anti-ferroptotic factor. The compound does not significantly inhibit other bromodomain-containing proteins, minimizing off-target effects (APExBIO).

Evidence & Benchmarks

• I-BET-762 exhibits potent BET inhibition with IC₅₀ values of 32.5–42.5 nM in biochemical assays (APExBIO).
• In HEK293T, HeLa, HepG2, RKO, and PC3 cell lines, I-BET-762 (2 μM) significantly enhances erastin-induced ferroptosis, as measured by cell viability assays and ROS accumulation (Fan et al. 2024).
• BRD4 inhibition by I-BET-762 downregulates FSP1 and alters the expression of ferroptosis-associated genes, with cell-type-dependent patterns (Fan et al. 2024).
• I-BET-762 administration in mouse models reduces LPS-induced inflammatory cytokine production and ameliorates symptoms of inflammatory disease (APExBIO).
• The compound is insoluble in water but dissolves at ≥21.19 mg/mL in DMSO and ≥13.93 mg/mL in ethanol under sonication; optimal storage is at -20°C (APExBIO).

This article extends the mechanistic detail and workflows outlined in 'I-BET-762: Advanced BET Inhibition for ROS-Driven Ferroptosis' by integrating new cell-line evidence and precise chemical parameters. For a broader translational perspective, see 'Redefining Epigenetic and Inflammatory Research', which this article updates with the latest mechanistic and benchmark findings.

Applications, Limits & Misconceptions

I-BET-762 is primarily used in research focused on:

• Epigenetic regulation and chromatin remodeling studies.
• Dissecting transcriptional regulation of LPS-inducible genes in inflammation models.
• Cancer biology, particularly in workflows targeting BET protein signaling and ferroptosis induction.
• Preclinical models of inflammatory diseases, where selective BET inhibition modulates disease phenotypes.

Common Pitfalls or Misconceptions

• I-BET-762 does not inhibit non-BET bromodomain proteins at effective concentrations; off-target bromodomain inhibition is negligible (APExBIO).
• The compound is insoluble in water; improper solvent use can result in precipitation and unreliable dosing.
• Prolonged storage of I-BET-762 in solution leads to degradation; solutions should be prepared fresh and used promptly.
• I-BET-762 is not a direct cytotoxic agent; its effects are mediated through transcriptional and epigenetic mechanisms.
• BET inhibition can have cell-type specific outcomes; gene expression changes may differ across experimental systems (Fan et al. 2024).

Workflow Integration & Parameters

For I-BET-762 (B1498, APExBIO), the recommended workflow involves dissolving the compound in DMSO to ≥21.19 mg/mL or in ethanol to ≥13.93 mg/mL with ultrasonic assistance. Storage should be at -20°C, protected from light. For cell culture studies, typical working concentrations are 1–2 μM, with treatment durations from 24 to 48 hours, depending on the assay and cell type (Fan et al. 2024). Controls should include solvent-only treatments to confirm specificity.

For combinatorial studies, I-BET-762 can be co-administered with ferroptosis inducers like erastin to evaluate synergistic effects on ROS and cell viability. Researchers should monitor for cell-type dependent responses, as gene expression modulation may vary. For guidance on integrating I-BET-762 into next-generation inflammation and epigenetics workflows, see the expanded protocol analysis in 'I-BET-762: Redefining Epigenetic Intervention and Ferroptosis Modulation', which this article extends by providing updated solubility and handling parameters.

Conclusion & Outlook

I-BET-762 (B1498, APExBIO) is a validated, highly selective BET inhibitor with robust utility in inflammation, cancer biology, and epigenetic research. Its nanomolar potency, high selectivity, and well-characterized mechanism facilitate reliable transcriptional modulation and ferroptosis enhancement in preclinical models. Researchers should adhere to strict solubility and storage guidelines to ensure experimental reproducibility. Future directions include combinatorial therapeutic strategies and expanded profiling in diverse cell types. For ordering and more details, refer to the official I-BET-762 product page.